Opdivo, Keytruda launches in India slated by end of 2016

Tricolor
Indian flag

Bristol-Myers Squibb's ($BMS) Opdivo and Merck's ($MRK) Keytruda could see launches in India by the end of 2016, setting up competition in a major out-of-pocket market in Asia after sales of both therapies have focused on reimbursement in Japan, Australia and New Zealand.

The Economic Times, citing health ministry sources, said Keytruda (pembrolizumab) won a nod from the Drug Controller General of India, while Opdivo (nivolumab) has a clinical trials waiver from earlier this year with indications in melanoma and NSCLC.

The regulatory clearances, according to industry sources cited by the newspaper, set up marketing authorization approvals likely in 2016.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Both drugs have been in focus in Japan on sales competition and reimbursement pricing by Japan's Central Social Insurance Medical Council--known as Chuikyo.

In the case of Opdivo price restrictions may come into play this month. Opdivo is sold in Japan through Ono Pharmaceuticals, which holds rights as it has a previous deal with the originator company bought by BMS, Medarex.

In Australia and New Zealand, price concerns have been raised by reimbursement agencies in countries with high rates of melanoma. Singapore also approved sales earlier this year. But China has not approved either therapy.

National reimbursement for essential drugs limited in India and cutting-edge therapies often come into the market via generic makers.

That raises the prospect of compulsory license applications locally such as Bayer's Nexavar (sorafenib) by Hyderabad-based Natco Pharmaceuticals.

Other pathways to cheaper costs include the manufacturing and sales licenses awarded to Indian firms by Gilead Sciences ($GILD) for hepatitis C therapies in about 100 developing markets.

Figures cited by the newspaper said Keytruda has $566 million in global sales in 2015 while Opdivo boasted $942 million, placing them on the road to blockbuster status.

But last week BMS reported that Opdivo failed to meet clinical trial targets for first-line NSCLC therapy, giving Merck a potential leg up in the indication.

- here's the story from The Economic Times

Related Articles:
BMS loses its lung cancer lead to Merck as Opdivo data comes up short
BMS provides figures on Opdivo contribution from Japan in Q2 call
BMS' Opdivo, Amgen's Repatha first on Japan's list for new price restrictions
New Zealand approves melanoma reimbursement for Opdivo
Merck has high Keytruda hopes outside U.S., but Q1 details sparse

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.